Vipulkumar Kantibhai Patel

USPTO Granted Patents = 23 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 42(Granted Patents)

Company Filing History:

8 out of 2,198

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property Development Limited

Biota Scientific Management Pty Ltd

patents

Years Active: 2001-2024

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11999746 - Compounds (2024-06-04),

2. 10793559 - Chemical compounds (2020-10-06),

3. 10457674 - Chemical compounds (2019-10-29),

4. 10428078 - Compounds (2019-10-01),

5. 10125141 - Compounds (2018-11-13),

6. 8633319 - 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors (2014-01-21),

7. 8470835 - Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase (2013-06-25),

8. 8383635 - Chemical compounds (2013-02-26),

9. 7750026 - Fused heteroaryl derivatives and their use as p38 kinase inhibitors (2010-07-06),

10. 7572790 - Biphenyl carboxylic amide p38 kinase inhibitors (2009-08-11),

11. 7517879 - Pyrrolidine derivatives as factor Xa inhibitors (2009-04-14),

12. 7429587 - Pyrrolidine derivatives as factor Xa inhibitors (2008-09-30),

13. 7338960 - Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators (2008-03-04),

14. 7326785 - Pyrrolidine derivatives as factor XA inhibitors (2008-02-05),

15. 7282497 - Pyrrolidin-2-one derivatives as inhibitors of factor xa (2007-10-16),

Title: Innovations by Vipulkumar Kantibhai Patel

Introduction

Vipulkumar Kantibhai Patel is an accomplished inventor based in Stevenage, GB. He is noted for his significant contributions to the field of chemical compounds and medical treatments, holding an impressive total of 23 patents. His work focuses primarily on compounds that inhibit specific enzymatic activities, particularly those associated with various diseases, including Alzheimer's.

Latest Patents

Vipulkumar's recent innovations include patents that highlight novel compounds aimed at inhibiting Lp-PLA activity, which is relevant in treating diseases associated with this enzymatic activity. His work is crucial in the fight against Alzheimer's disease. Another significant patent involves the development of certain novel chemical compounds that serve as inhibitors of kinase activity, particularly for PI3-kinase. These advancements represent a step forward in therapeutic applications and showcase his innovative capabilities.

Career Highlights

Throughout his career, Vipulkumar has made remarkable contributions while working with prominent firms such as SmithKline Beecham Corporation and Glaxo Group Limited. His experiences in these companies have played a vital role in shaping his research and innovation path, allowing him to develop impactful solutions in pharmaceuticals.

Collaborations

Vipulkumar’s journey is supported by a network of dedicated professionals. Notable colleagues, including Julie Nicole Hamblin and Nigel Paul King, have collaborated with him to advance research and foster breakthroughs in their shared fields of expertise.

Conclusion

Vipulkumar Kantibhai Patel continues to be a driving force in the realm of innovative compounds and treatments. His extensive portfolio of patents reflects his commitment to research and development, demonstrating his essential role in addressing critical health challenges through scientific innovation. As he continues to explore new frontiers, his work promises to have a lasting impact on the industry and on patients worldwide.

This text is generated by artificial intelligence and may not be accurate.